Efficient Prodrug Activator Gene Therapy by Retroviral Replicating Vectors Prolongs Survival in an Immune-Competent Intracerebral Glioma Model. [PDF]
, 2020 Prodrug activator gene therapy mediated by murine leukemia virus (MLV)-based retroviral replicating vectors (RRV) was previously shown to be highly effective in killing glioma cells both in culture and in vivo.
Chang, Deching +13 more
core +2 more sources
The Oncolytic Virus in Cancer Diagnosis and Treatment
Frontiers in Oncology, 2020 Cancer has always been an enormous threat to human health and survival. Surgery, radiotherapy, and chemotherapy could improve the survival of cancer patients, but most patients with advanced cancer usually have a poor survival or could not afford the ...
Guo-dong Cao +9 more
doaj +1 more source
Molecular Therapy: Oncolytics, 2019 The efficacy of immune checkpoint blockade therapy against immunologically “cold” tumors can be enhanced by applying the checkpoint inhibitors in combination with oncolytic viruses.
Yujie Zhu +9 more
doaj +1 more source
Adaptation of transgene mRNA translation boosts the anticancer efficacy of oncolytic HSV1
Journal for ImmunoTherapy of Cancer, 2023 Background Transgenes deliver therapeutic payloads to improve oncolytic virus immunotherapy. Transgenes encoded within oncolytic viruses are designed to be highly transcribed, but protein synthesis is often negatively affected by viral infection ...
Huy-Dung Hoang +15 more
doaj +1 more source
Atomic Resolution Structure of the Oncolytic Parvovirus LuIII by Electron Microscopy and 3D Image Reconstruction. [PDF]
, 2017 LuIII, a protoparvovirus pathogenic to rodents, replicates in human mitotic cells, making it applicable for use to kill cancer cells. This virus group includes H-1 parvovirus (H-1PV) and minute virus of mice (MVM).
Agbandje-McKenna, Mavis +13 more
core +3 more sources
YB-1 dependent oncolytic adenovirus efficiently inhibits tumor growth of glioma cancer stem like cells [PDF]
, 2013 Background: The brain cancer stem cell (CSC) model describes a small subset of glioma cells as being responsible for tumor initiation, conferring therapy resistance and tumor recurrence.
Beier, Dagmar +9 more
core +1 more source
Oncolytic potency and reduced virus tumor-specificity in oncolytic virotherapy. A mathematical modelling approach. [PDF]
PLoS ONE, 2017 In the present paper, we address by means of mathematical modeling the following main question: How can oncolytic virus infection of some normal cells in the vicinity of tumor cells enhance oncolytic virotherapy?
Khaphetsi Joseph Mahasa +3 more
doaj +1 more source
Research progress of oncolytic virus combined with PD-1/PD-L1 inhibitors [PDF]
Jichu yixue yu linchuang, 2022 Oncolytic viruses are often used in combination with immune checkpoint inhibitors represented in two ways by programmed cell death 1/programmed cell death-Ligand 1 (PD-1/PD-L1).
GAN Zi-ying, TANG Hui
doaj +1 more source
Biological therapy in the treatment of melanoma [PDF]
, 2018 Melanoma is one of the most aggressive tumors and its incidence is on the rise. The low rates of survival in metastatic melanoma has led to the development of new drugs for this type of patient, such as biological therapy which has shown remarkable ...
Benea, Vasile +8 more
core +3 more sources
Therapeutic Potential of Mesenchymal Stem Cells for Cancer Therapy [PDF]
, 2020 Mesenchymal stem cells (MSCs) are among the most frequently used cell type for regenerative medicine. A large number of studies have shown the beneficial effects of MSC-based therapies to treat different pathologies, including neurological disorders ...
Capilla González, Vivian +4 more
core +1 more source